Brain metastases, as a very common complication of malignant tumors, pose a threat to the life of patients with malignant tumors. Historically, radiotherapy has been the mainstay of treatment, including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), etc. With the advent of targeted therapy and immunotherapy, there are more options for the treatment of brain metastases. However, how to choose a more reasonable treatment plan for patients is particularly important. Under the premise that targeted therapy and immunotherapy have good therapeutic effects on brain metastases, some researchers believe that radiotherapy can be omitted due to the impact of radiotherapy on cognition, but there is no convincing evidence that we can give up or defer radiotherapy in brain metastases. Therefore, whether target treatment, immunotherapy or radiotherapy is more suitable as the first-line treatment in brain metastases, some prospective clinical studies are needed to further identify, and relevant basic research is also welcome. The goal of this solicitation is to provide a reference for precise treatment strategies for brain metastases and maximize the therapeutic benefit of patients.
We welcome submissions within the scope of this Research Topic covering, but not limited to, the following subtopics:
1. Prospective clinical studies comparing the clinical effects of radiotherapy with targeted therapy or immunotherapy in first-line treatment based on aberrant molecular phenotype.
2. Studies on the mechanism of radioresistance for radiotherapy in brain metastases.
3. Development of biomarkers that can help identify optimal treatment strategies for specific patients.
4. Radiosensitization strategies related to radiotherapy in brain metastases, such as regulating some aberrant molecular phenotype, using biomaterials to improve drug delivery, and so on.
Please note: basic research without clinical guiding value is outside the scope of this Research Topic. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Brain metastases, as a very common complication of malignant tumors, pose a threat to the life of patients with malignant tumors. Historically, radiotherapy has been the mainstay of treatment, including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), etc. With the advent of targeted therapy and immunotherapy, there are more options for the treatment of brain metastases. However, how to choose a more reasonable treatment plan for patients is particularly important. Under the premise that targeted therapy and immunotherapy have good therapeutic effects on brain metastases, some researchers believe that radiotherapy can be omitted due to the impact of radiotherapy on cognition, but there is no convincing evidence that we can give up or defer radiotherapy in brain metastases. Therefore, whether target treatment, immunotherapy or radiotherapy is more suitable as the first-line treatment in brain metastases, some prospective clinical studies are needed to further identify, and relevant basic research is also welcome. The goal of this solicitation is to provide a reference for precise treatment strategies for brain metastases and maximize the therapeutic benefit of patients.
We welcome submissions within the scope of this Research Topic covering, but not limited to, the following subtopics:
1. Prospective clinical studies comparing the clinical effects of radiotherapy with targeted therapy or immunotherapy in first-line treatment based on aberrant molecular phenotype.
2. Studies on the mechanism of radioresistance for radiotherapy in brain metastases.
3. Development of biomarkers that can help identify optimal treatment strategies for specific patients.
4. Radiosensitization strategies related to radiotherapy in brain metastases, such as regulating some aberrant molecular phenotype, using biomaterials to improve drug delivery, and so on.
Please note: basic research without clinical guiding value is outside the scope of this Research Topic. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
